藥品成本控制政策及醫師獎勵金制度對全民健保門診費用影響之實證研究
Date Issued
2002
Date
2002
Author(s)
DOI
902416H002012
Abstract
This study uses variance cost analysis and regression analysis as tools for
investigating the initial effects of Taiwan’s outpatient prescription drug co-payment
program in the elderly. Under its new National Health Insurance program, Taiwan
implemented a prescription drug cost-sharing program August 1, 1999. We compare
an elderly population’s prescription drug use after the policy was implemented, with
an elderly population’s prescription drug use prior to the policy change, to describe
initial and general consequences of the drug cost-sharing program. Thus the research
may be instructive for the US and other countries that struggle with providing
prescription benefits to their elderly population within economic constraints.
The significant increase in average drug price per prescription indicates that many
prescriptions may move above the upper bound of the cost-sharing schedule. The
results suggest that the Bureau of National Health Insurance should increase the upper
bound. We do not think that these effects are unique to Taiwan. Rather, these effects
should be considered as countries change their outpatient drug benefit programs. We
also found a decrease in utilization of essential drugs while an increase in utilization of
non-essential drugs for patients subject to co-payments. The results suggest potential
adverse effects on patients’ health outcome.
Subjects
cost-sharing
outpatient prescription drug
Taiwan’s National Health Insurance
Publisher
臺北市：國立臺灣大學會計學系暨研究所
Type
report
File(s)![Thumbnail Image]()
Loading...
Name
902416H002012.pdf
Size
80.48 KB
Format
Adobe PDF
Checksum
(MD5):517f7b40c3fa9b41654f36ed804b78b9